Dr. David Johnson, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Georgia School of Medicine (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 39
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Medical College of Georgia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license N8409 (first issued 2011; active) · TN license MD13476
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 39
- Services billed
- 165
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 65 | 20 |
| Hospital discharge day management, 30 minutes or less | 21 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 22 payments worth $48,352 in total to this clinician.
| AstraZeneca UK Limited | $35,792 |
|---|---|
| Merck Sharp & Dohme LLC | $9,410 |
| Gilead Sciences, Inc. | $3,150 |
| Consulting Fee | $48,352 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Nov 20, 2025 | Consulting Fee DATROWAY · Oncology | $4,795 |
| Gilead Sciences, Inc. May 13, 2025 | Consulting Fee Trodelvy · ONC Company’s description;3983061;SAP;10759126 | $3,150 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee DATROWAY · Oncology | $3,083 |
| AstraZeneca UK Limited Jul 25, 2025 | Consulting Fee DATROWAY · Oncology | $2,911 |
| AstraZeneca UK Limited Oct 23, 2025 | Consulting Fee DATROWAY · Oncology | $2,740 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee DATROWAY · Oncology | $2,569 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee ENHERTU · Oncology | $2,569 |
| AstraZeneca UK Limited May 2, 2025 | Consulting Fee DATROWAY · Oncology | $2,569 |
| AstraZeneca UK Limited Jul 25, 2025 | Consulting Fee DATROWAY · Oncology | $2,227 |
| AstraZeneca UK Limited Apr 24, 2025 | Consulting Fee DATROWAY · Oncology | $2,226 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Nov 20, 2025 | Consulting Fee DATROWAY · Oncology | $4,795 |
| Merck Sharp & Dohme LLC Nov 12, 2025 | Consulting Fee KEYTRUDA QLEX · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,525 |
| AstraZeneca UK Limited Oct 30, 2025 | Consulting Fee DATROWAY · Oncology | $1,713 |
| AstraZeneca UK Limited Oct 23, 2025 | Consulting Fee DATROWAY · Oncology | $2,740 |
| AstraZeneca UK Limited Sep 11, 2025 | Consulting Fee DATROWAY · Oncology | $1,541 |
| AstraZeneca UK Limited Aug 21, 2025 | Consulting Fee ENHERTU · Oncology | $1,884 |
| AstraZeneca UK Limited Jul 25, 2025 | Consulting Fee DATROWAY · Oncology | $2,911 |
| AstraZeneca UK Limited Jul 25, 2025 | Consulting Fee DATROWAY · Oncology | $2,227 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,500 |
| AstraZeneca UK Limited Jul 10, 2025 | Consulting Fee DATROWAY · Oncology | $2,226 |
| Merck Sharp & Dohme LLC Jun 18, 2025 | Consulting Fee LYNPARZA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $2,135 |
| AstraZeneca UK Limited May 16, 2025 | Consulting Fee DATROWAY · Oncology | $1,370 |
| Gilead Sciences, Inc. May 13, 2025 | Consulting Fee Trodelvy · ONC Company’s description;3983061;SAP;10759126 | $3,150 |
| AstraZeneca UK Limited May 2, 2025 | Consulting Fee DATROWAY · Oncology | $2,569 |
| AstraZeneca UK Limited Apr 24, 2025 | Consulting Fee DATROWAY · Oncology | $2,226 |
| AstraZeneca UK Limited Feb 14, 2025 | Consulting Fee DATROWAY · Oncology | $1,370 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee DATROWAY · Oncology | $3,083 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee DATROWAY · Oncology | $2,569 |
| AstraZeneca UK Limited Jan 31, 2025 | Consulting Fee ENHERTU · Oncology | $2,569 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,750 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,250 |
| Merck Sharp & Dohme LLC Jan 13, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.